Search

Displaying results 3471 - 3480 of 5419 in total
  1. Drug

    Clofoctol

    go.drugbank.com/drugs/DB13237
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This is a novel therapeutic approach to ...

  3. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a result, CT...

  4. Drug

    Tezacitabine

    go.drugbank.com/drugs/DB06433
    Investigational

    A synthetic purine nucleoside analogue with potential antineoplastic activity.

  5. Drug

    SNS-032

    go.drugbank.com/drugs/DB05969
    Investigational

  6. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015.

  7. Drug

    Recombinant alpha 1-antitrypsin

    go.drugbank.com/drugs/DB05481
    Investigational

    Alpha 1-antitrypsin is a glycoprotein primarily produced by hepatocytes, and to a lesser extent, immune system cells.

  8. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  9. Drug

    Pyrrolnitrin

    go.drugbank.com/drugs/DB13603
    Experimental

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  10. Drug

    Oxibendazole

    go.drugbank.com/drugs/DB04910
    ExperimentalVet approved

    Oxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.